DDInter1042 DDInter1124
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does not appear to block serotonin reuptake. Maprotiline may be used to treat depressive affective disorders, including dysthymic disorder (depressive neurosis) and major depressive disorder. Maprotiline is effective at reducing symptoms of anxiety associated with depression.
Maprotiline {u} (Compound) resembles {v} (Compound) Protriptyline
Maprotiline {u} (Compound) resembles {v} (Compound) Demexiptiline
Maprotiline {u} (Compound) binds {v} (Gene) ABCB1
Maprotiline {u} (Compound) upregulates {v} (Gene) UBE2L6
Maprotiline {u} (Compound) palliates {v} (Disease) panic disorder
Maprotiline {u} (Compound) downregulates {v} (Gene) CCNA2
Maprotiline {u} (Compound) causes {v} (Side Effect) Angiopathy
Maprotiline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Maprotiline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ephedrine
Maprotiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sunitinib
Maprotiline (Compound) resembles Protriptyline (Compound)
Maprotiline (Compound) resembles Demexiptiline (Compound)
Maprotiline (Compound) binds ABCB1 (Gene)
Maprotiline (Compound) upregulates UBE2L6 (Gene)
Maprotiline (Compound) palliates panic disorder (Disease)
Maprotiline (Compound) downregulates CCNA2 (Gene)
Maprotiline (Compound) causes Angiopathy (Side Effect)
Maprotiline may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Maprotiline may cause a minor interaction that can limit clinical effects when taken with Ephedrine
Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib